Cases & Deals

Puma Biotechnology defends European patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer in opposition proceedings

Clients Puma Biotechnology, Inc.

Jones Day represents Puma Biotechnology, Inc. in European opposition proceedings initiated by Hexal to defend a patent licensed from Pfizer covering Neratinib extended adjuvant therapy for HER2+ breast cancer.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.